Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | TARS1 | P26639 | 3/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | PRKACG | P22612 | 1/20 | 0.32 |
| ▸ | PRKACB | P22694 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168673 | 0.76 | HTT (0.53) | HTTDHFR | |
| SCHEMBL10015393 | 0.76 | HTT (0.49) | HTTTARS1DHFR | |
| SCHEMBL21500731 | 0.72 | HTT (0.68) | HTTHTR3AHRH4 | |
| SCHEMBL3314521 | 0.72 | NR4A2 (0.53) | HTTMAP4K4LMNADHFRHTR3A | |
| SCHEMBL29441517 | 0.72 | HTT (0.68) | HTTHTR3AHRH4 | |
| SCHEMBL611438 | 0.72 | POLB (0.59) | HTTEGFRKDRLMNA | |
| SCHEMBL29642054 | 0.72 | POLB (0.59) | HTTEGFRKDRLMNA | |
| SCHEMBL20620603 | 0.72 | ADORA2A (0.37) | HTTLMNADHFR | |
| SCHEMBL20620308 | 0.72 | CNR1 (0.34) | LMNADHFR | |
| SCHEMBL31693082 | 0.71 | HTT (0.51) | HTTEGFRMAP4K4DHFRNQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408092-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | UNIV CASE WESTERN RESERVE (US) | 2024-12-12 | — | — | US | disclosed |
| US-11944624-B2 | Peptide and small molecule agonists of EphA and their uses | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20200222405-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY | 2020-07-16 | — | — | US | disclosed |
| US-20200222405-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY | 2020-07-16 | — | — | US | disclosed |
| EP-3648766-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | Case Western Reserve University (US) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019010180-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019010180-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-01-10 | — | — | WO | disclosed |
| US-8377948-B2 | Antitumor agents and methods of their use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008021891-A2 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2006002088-A2 | AMINO-QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222405-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | EPHA1, EPHA7, EPHA3 | HTT 4807/4885EGFR 26/4885KDR 258/4885 |
| US-11944624-B2 | Peptide and small molecule agonists of EphA and their uses | EPHA1, EPHA7, EPHA3 | HTT 4807/4885EGFR 26/4885KDR 258/4885 |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | ADRB1, ADRA2A, ADRA1A | HTT 4801/4885EGFR 2789/4885KDR 381/4885 |
| US-20240408092-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | EPHA1, EPHA7, EPHA3 | HTT 4807/4885EGFR 26/4885KDR 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.